5-Amino-1MQ Reconstitution Calculator

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide (NAM) using S-adenosyl-methionine (SAM), producing 1-methylnicotinamide, depleting NAD+ precursors, and raising homocysteine. Inhibiting NNMT preserves NAM and SAM, increases intracellular NAD+ and SAM, and suppresses lipogenesis in adipocytes. Evidence: preclinical (animal/mechanistic).

No. It has no FDA approval and no human clinical trials. All published efficacy and safety data are from animals and cell lines. It is sold as a research chemical, not a licensed medicine or dietary supplement.

No human dose is established. In aged mice, NNMTi at 5 and 10 mg/kg/day for 1–3 weeks improved muscle stem cell proliferation and myofiber cross-sectional area. Aged mice treated with NNMTi for ~8 weeks showed ~40% greater grip strength. In diet-induced obese mice, NNMTi with low-fat diet normalized body composition and liver adiposity. In vitro, the related methylquinolinium compound 5MQ inhibited HeLa proliferation at 0.1–500 μM. Community protocols list subcutaneous doses of 2–20 mg once daily; allometric equivalent from 10 mg/kg mouse is 44–81 mg/day, but community starting range is 5–30 mg/day; this is not validated by human trials (community protocol).

No human comparative data exist. In animals, systemic administration was used; methylquinolinium analogues with primary amine substitutions showed high membrane permeability in Caco-2 assays, supporting oral absorption potential. Community practitioners may prefer subcutaneous injection for control of bioavailability, but oral use is also reported (community protocol).

No long-term human data. Preclinical durations: 1–3 weeks post-injury; ~8 weeks in aged mice; obesity studies combined NNMTi with diet for several weeks. Community cycles commonly run 8–12 weeks, but this lacks human evidence (community protocol).

Human safety unknown. In diet-induced obese mice, NNMTi did not alter food intake and produced no observable adverse effects. However, NNMT has tissue-specific functions and its metabolite 1-MNA may have protective cardiovascular effects; chronic inhibition has not been tested in humans. Theoretical risks include altered methylation balance and homocysteine dynamics.

No. No reproductive, developmental, or lactation safety data exist. Avoid use in pregnancy and breastfeeding.

In diet-induced obese mice, NNMTi combined with lean diet normalized body weight and fat mass, decreased liver adiposity, improved hepatic steatosis, and increased lean mass ratio. NNMTi also reduced body weight, white adipose mass, adipocyte size, and plasma cholesterol in high-fat-diet mice. NNMT inhibition or knockdown reduces body weight, increases energy expenditure, and improves glucose tolerance in preclinical models. Human fat-loss efficacy is unproven (animal).